BeOne Medicines Ltd. - Sponsored ADR ONC
360.85
0.88
0.24%
as of 25 Sep
- Market cap
- $37.3B
- P/E
- 61.2×
Follow ONC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
1.81% | 7.46% | 12.42% | 14.66% | |
| 1.02% | 4.07% | 7.13% | 8.47% | ||
ROIC |
49.21% | 36.03% | 46.03% | 60.22% | |
Return on Tangible Assets |
1.39% | 4.75% | 7.98% | 9.73% | |
Average Days of Receivables |
63.37 | 59.10 | 59.66 | 62.90 | |
Free Cash Flow per Share |
4.76 | 8.45 | 10.05 | 11.92 | |
Free Cash Flow |
524.60 | 921.74 | 1,114.61 | 1,330.19 | |
Capital Expenditures |
(260.80) | (205.84) | (170.22) | (153.87) | |
Piotroski F-Score |
8.00 | 7.00 | 7.00 | 7.00 | |
| Other line items | |||||
Cash ROIC |
9.46% | 11.42% | 12.22% | 13.30% | |
Accounts Receivable Turnover |
6.94 | 6.93 | 6.93 | 6.71 | |
Accounts Payable Turnover |
1.99 | 1.51 | 1.70 | 1.64 | |
Inventory Turnover |
1.43 | 1.21 | 1.14 | 1.10 | |
Average Days of Payables |
203.94 | 261.54 | 230.48 | 252.19 | |
Days of Inventory on Hand |
282.62 | 332.07 | 370.90 | 392.84 | |
Tax Rate |
(0.62) | (0.31) | (0.22) | (0.24) | |
Research and Development Expense of Revenue |
41.68% | 40.16% | 38.42% | 37.41% | |
Selling, General and Administrative Expense of Revenue |
40.84% | 38.96% | 37.94% | 36.43% | |
Share Based Compensation of Revenue |
9.95% | 9.56% | 9.39% | 8.57% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
11.46 | 3.93 | 2.50 | 2.26 | |
Depreciation/Fixed assets |
0.10 | 0.09 | 0.09 | 0.09 | |
Capex/Depreciation |
(1.67) | (1.45) | (1.13) | (0.99) | |
Revenue per Share |
45.12 | 48.99 | 51.72 | 54.93 | |
Operating CF per Share |
7.13 | 10.34 | 11.58 | 13.30 | |
Capex per Share |
(2.37) | (1.89) | (1.53) | (1.38) | |
Capex to Sales |
0.05 | 0.04 | 0.03 | 0.03 | |
Net Profit Margin |
1.38% | 5.37% | 8.94% | 10.70% |
Columns are period end dates